<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36938851</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>05</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1756-185X</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>9</Issue><PubDate><Year>2023</Year><Month>Sep</Month></PubDate></JournalIssue><Title>International journal of rheumatic diseases</Title><ISOAbbreviation>Int J Rheum Dis</ISOAbbreviation></Journal><ArticleTitle>Montelukast as a treatment for refractory cutaneous lupus: A&#xa0;case series.</ArticleTitle><Pagination><StartPage>1816</StartPage><EndPage>1820</EndPage><MedlinePgn>1816-1820</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/1756-185X.14671</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">There are no drugs specifically approved to treat cutaneous lupus. Inflammatory cells in lupus skin lesions can produce leukotrienes (LT), which promote tissue damage. In addition to hypersensitivity reactions, LT are also associated with cardiovascular diseases and elevated serum LT levels have been linked to worse atherosclerotic disease in lupus. Targeting LT could thus be an alternative to treat lupus. We present 4 cases of cutaneous lupus successfully treated with montelukast (MLK), a Cys-LT antagonist.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Four consecutive female systemic lupus erythematosus (SLE) patients with refractory skin lesions were treated with MLK (10&#xa0;mg/d) in the Hospital Universit&#xe1;rio Walter Cant&#xed;dio of the Universidade Federal do Cear&#xe1;. Skin lesions were scored using Revised Cutaneous LE Disease Area and Severity Index (RCLASI). Relative expression of the 5-lipoxigenase (ALOX5) and 15-lipoxigenase (ALOX15) genes was determined in peripheral blood cells (PBC) from lupus patients and 4 age-matched female controls.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">All patients experienced improvement of skin lesions measured using RCLASI scores within 2-12&#x2009;weeks following initiation of MLK. The response was sustained for at least 3&#xa0;months follow-up and no adverse events were recorded. ALOX5 but not ALOX15 gene expression was significantly (P&#xa0;=&#xa0;0.0425) increased in PBC from SLE patients vs controls.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This is the first report of a fast and sustained successful response of cutaneous lupus to MLK. Given its acceptable safety profile, our data encourage development of a randomized trial as an attempt to reposition MLK as a safe, affordable alternative to treat cutaneous lupus.</AbstractText><CopyrightInformation>&#xa9; 2023 Asia Pacific League of Associations for Rheumatology and John Wiley &amp; Sons Australia, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rocha</LastName><ForeName>Francisco Airton Castro</ForeName><Initials>FAC</Initials><Identifier Source="ORCID">0000-0003-4370-3294</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine-Faculdade de Medicina, Universidade Federal do Cear&#xe1;, Fortaleza, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>da Silva</LastName><ForeName>Guilherme Ferreira Maciel</ForeName><Initials>GFM</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine-Faculdade de Medicina, Universidade Federal do Cear&#xe1;, Fortaleza, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nogueira</LastName><ForeName>Igor Albuquerque</ForeName><Initials>IA</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine-Faculdade de Medicina, Universidade Federal do Cear&#xe1;, Fortaleza, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nunes</LastName><ForeName>Rodolfo de Melo</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine-Faculdade de Medicina, Universidade Federal do Cear&#xe1;, Fortaleza, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martins</LastName><ForeName>Concei&#xe7;&#xe3;o da Silva</ForeName><Initials>CDS</Initials><AffiliationInfo><Affiliation>Postgraduate Program in Morphofunctional Sciences-Department of Morphology-Faculdade de Medicina, Universidade Federal do Cear&#xe1;, Fortaleza, Brazil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Conselho Nacional de Desenvolvimento Cient&#xed;fico e Tecnol&#xf3;gico</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Rheum Dis</MedlineTA><NlmUniqueID>101474930</NlmUniqueID><ISSNLinking>1756-1841</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>MHM278SD3E</RegistryNumber><NameOfSubstance UI="C093875">montelukast</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008178" MajorTopicYN="Y">Lupus Erythematosus, Cutaneous</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012867" MajorTopicYN="N">Skin</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000279" MajorTopicYN="N">Administration, Cutaneous</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">inflammation</Keyword><Keyword MajorTopicYN="N">leukotrienes</Keyword><Keyword MajorTopicYN="N">lipoxygenase</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus</Keyword><Keyword MajorTopicYN="N">therapeutics</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>2</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>5</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>20</Day><Hour>5</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36938851</ArticleId><ArticleId IdType="doi">10.1111/1756-185X.14671</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Hile GA, Kahlenberg JM. Immunopathogenesis of skin injury in systemic lupus erythematosus. Curr Opin Rheumatol. 2021;33(2):173-180. doi:10.1097/bor.0000000000000770</Citation></Reference><Reference><Citation>Kuhn A, Aberer E, Bata-Cs&#xf6;rg&#x151; Z, et al. S2k guideline for treatment of cutaneous lupus erythematosus - guided by the European dermatology forum (EDF) in cooperation with the European academy of dermatology and venereology (EADV). J Eur Acad Dermatol Venereol. 2017;31(3):389-404. doi:10.1111/jdv.14053</Citation></Reference><Reference><Citation>Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736-745. doi:10.1136/annrheumdis-2019-215089</Citation></Reference><Reference><Citation>Laosakul K, Chiewchanvit S, Chuamanochan M, Tavanabutra N. Acitretin treatment in antimalarial-refractory/intolerant discoid lupus erythematosus: a prospective, open-label, uncontrolled study. Lupus. 2022;31(5):575-581. doi:10.1177/09612033221086878</Citation></Reference><Reference><Citation>Malara G, Verduci C, Altomonte M, et al. Thalidomide and discoid lupus erythematosus: case series and review of literature. Drugs Context. 2022;11:1-10. doi:10.7573/dic.2021-9-8</Citation></Reference><Reference><Citation>Neubert E, Bach KM, Busse J, et al. Blue and long-wave ultraviolet light induce in vitro neutrophil extracellular trap (NET) formation. Front Immunol. 2019;10:2428. doi:10.3389/fimmu.2019.02428</Citation></Reference><Reference><Citation>Korotkova M, Jakobsson PJ. Persisting eicosanoid pathways in rheumatic diseases. Nat Rev Rheumatol. 2014;10(4):229-241. doi:10.1038/nrrheum.2014.1</Citation></Reference><Reference><Citation>Haeggstr&#xf6;m JZ. Leukotriene biosynthetic enzymes as therapeutic targets. J Clin Invest. 2018;128(7):2680-2690. doi:10.1172/jci97945</Citation></Reference><Reference><Citation>Baig S, Vanarsa K, Ding H, ASCLS T, McMahon M, Mohan C. Baseline Elevations of Leukotriene Metabolites and Altered Plasmalogens Are Prognostic Biomarkers of Plaque Progression in Systemic Lupus Erythematosus. Front Cardiovasc Med. 2022;9:861724. doi:10.3389/fcvm.2022.861724 eCollection 2022.</Citation></Reference><Reference><Citation>Chu J, Pratic&#xf2; D. The 5-lipoxygenase as modulator of Alzheimer's &#x3b3;-secretase and therapeutic target. Brain Res Bull. 2016;126(pt 2):207-212. doi:10.1016/j.brainresbull.2016.03.010</Citation></Reference><Reference><Citation>Di Gennaro A, Haeggstr&#xf6;m JZ. The leukotrienes: immune-modulating lipid mediators of disease. Adv Immunol. 2012;116:51-92. doi:10.1016/b978-0-12-394300-2.00002-8</Citation></Reference><Reference><Citation>Kuhn A, Meuth AM, Bein D, et al. Revised cutaneous lupus erythematosus disease area and severity index (RCLASI): a modified outcome instrument for cutaneous lupus erythematosus. Br J Dermatol. 2010;163(1):83-92. doi:10.1111/j.1365-2133.2010.09799.x</Citation></Reference><Reference><Citation>Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25(4):402-408. doi:10.1006/meth.2001.1262</Citation></Reference><Reference><Citation>Bonnardeaux E, Dutz JP. Oral tofacitinib citrate for recalcitrant cutaneous lupus. JAAD Case Rep. 2021;20:61-64. doi:10.1016/j.jdcr.2021.09.030</Citation></Reference><Reference><Citation>Kasitanon N, Hamijoyo L, Li MT, et al. Management of non-renal manifestations of systemic lupus erythematosus: a systematic literature review for the APLAR consensus statements. Int J Rheum Dis. 2022;25(11):1220-1229. doi:10.1111/1756-185X.14413</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>